Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2

被引:71
|
作者
Muchtaridi, Muchtaridi [1 ]
Fauzi, M. [1 ]
Ikram, Nur Kusaira Khairul [2 ,3 ]
Gazzali, Amirah Mohd [4 ]
Wahab, Habibah A. [5 ]
机构
[1] Univ Padjadjaran, Fac Pharm, Dept Pharmaceut Anal & Med Chem, Jl Raya 21-5, Bandung 45363, Indonesia
[2] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur 50603, Malaysia
[3] Univ Malaya, Ctr Res Biotechnol Agr CEBAR, Kuala Lumpur 50603, Malaysia
[4] Univ Sains Malaysia, Sch Pharmaceut Sci, Dept Pharmaceut Technol, Gelugor 11800, Penang, Malaysia
[5] Univ Sains Malaysia, Sch Pharmaceut Sci, Pharmaceut Design & Simulat Lab, Gelugor 11800, Penang, Malaysia
来源
MOLECULES | 2020年 / 25卷 / 17期
关键词
ACE2; COVID-19; flavonoid; coronavirus; RESPIRATORY SYNDROME CORONAVIRUS; SPIKE PROTEIN; SARS-COV; RECEPTOR EXPRESSION; ACE2; SARS-COV-2; DISCOVERY; ENTRY; COVID-19; PRODUCTS;
D O I
10.3390/molecules25173980
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Over the years, coronaviruses (CoV) have posed a severe public health threat, causing an increase in mortality and morbidity rates throughout the world. The recent outbreak of a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the current Coronavirus Disease 2019 (COVID-19) pandemic that affected more than 215 countries with over 23 million cases and 800,000 deaths as of today. The situation is critical, especially with the absence of specific medicines or vaccines; hence, efforts toward the development of anti-COVID-19 medicines are being intensively undertaken. One of the potential therapeutic targets of anti-COVID-19 drugs is the angiotensin-converting enzyme 2 (ACE2). ACE2 was identified as a key functional receptor for CoV associated with COVID-19. ACE2, which is located on the surface of the host cells, binds effectively to the spike protein of CoV, thus enabling the virus to infect the epithelial cells of the host. Previous studies showed that certain flavonoids exhibit angiotensin-converting enzyme inhibition activity, which plays a crucial role in the regulation of arterial blood pressure. Thus, it is being postulated that these flavonoids might also interact with ACE2. This postulation might be of interest because these compounds also show antiviral activity in vitro. This article summarizes the natural flavonoids with potential efficacy against COVID-19 through ACE2 receptor inhibition.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection
    Chodick, Gabriel
    Nutman, Amir
    Yiekutiel, Naama
    Shalev, Varda
    JOURNAL OF TRAVEL MEDICINE, 2020, 27 (05)
  • [22] Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review
    Singh, Bhagat
    Singh, Dheer
    Verma, Vinod
    Yadav, Ramakant
    Kumar, Raj
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2022, 12 (02) : 215 - 220
  • [23] Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
    Wu, Ching-Yuan
    Lin, Yu-Shih
    Yang, Yao-Hsu
    Shu, Li-Hsin
    Cheng, Yu-Ching
    Liu, Hung Te
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [24] Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection
    Alabsi, Sarah
    Dhole, Atharva
    Hozayen, Sameh
    Chapman, Scott A.
    MICROORGANISMS, 2023, 11 (03)
  • [25] Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)
    Verma, Surjeet
    Twilley, Danielle
    Esmear, Tenille
    Oosthuizen, Carel B.
    Reid, Anna-Mari
    Nel, Marize
    Lall, Namrita
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [26] Angiotensin-converting enzyme 2: A protective factor in regulating disease virulence of SARS-COV-2
    Mariappan, Vignesh
    Rao, S. R.
    Pillai, Agieshkumar Balakrishna
    IUBMB LIFE, 2020, 72 (12) : 2533 - 2545
  • [27] The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination of in silico methods for treatment of COVID-19
    Zarezade, Vahid
    Rezaei, Hamzeh
    Shakerinezhad, Ghodratollah
    Safavi, Arman
    Nazeri, Zahra
    Veisi, Ali
    Azadbakht, Omid
    Hatami, Mahdi
    Sabaghan, Mohamad
    Shajirat, Zeinab
    JOURNAL OF MOLECULAR STRUCTURE, 2021, 1237
  • [28] Autoantibodies targeting angiotensin-converting enzyme 2 are prevalent and not induced by SARS-CoV-2 infection
    Galipeau, Yannick
    Castonguay, Nicolas
    Mccluskie, Pauline S.
    Sonoda, Mayra Trentin
    Keeshan, Alexa
    Collins, Erin
    Arnold, Corey
    Pelchat, Martin
    Burns, Kevin
    Cooper, Curtis
    Langlois, Marc-Andre
    FASEB JOURNAL, 2025, 39 (04)
  • [29] Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
    Kriszta, Gabor
    Kriszta, Zsofia
    Vancsa, Szilard
    Hegyi, Peter Jeno
    Frim, Levente
    Eross, Balint
    Hegyi, Peter
    Petho, Gabor
    Pinter, Erika
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [30] Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?
    Infusino, Fabio
    Cimino, Sara
    Lombardi, Marco
    Mancone, Massimo
    Cavarretta, Elena
    Frati, Giacomo
    Pugliese, Francesco
    Fedele, Francesco
    Biondi Zoccai, Giuseppe
    MINERVA CARDIOANGIOLOGICA, 2020, 68 (04): : 339 - 346